TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05499299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Google ads
Description: Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Google ads
Description: Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Google ads
Description: Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Google ads
Description: Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Google ads
Description: Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Google ads
Description: Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Google ads
Description: Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website
Study: NCT05029154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise
Description: Patients in the exercise group will perform interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Patients will undergo 2 initial training sessions at the exercise physiology core lab. All exercise will consist of stationary cycling to avoid discomfort associated with abdominal surgery as well as stress to the incision and help reduce fall risk. Study investigators will check in weekly with participants and remotely track exercise data and compliance via the Fitbit app.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention control
Description: Patients in the control group (physical activity education and physical activity monitoring) will receive counseling regarding the benefits of physical activity during chemotherapy treatment. During the intervention, participants will receive a weekly phone call to discuss their physical activity and remind them to engage in physical activity. Patients will be given a goal of working up to 30 minutes of exercise daily. Subjects will be urged to increase daily step counts by 250-500 steps/day. Physical activity will be objectively assessed and made available to the participant using a Fitbit.
Study: NCT06342531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eDASA+APP FI
Description: A CDSS for nurses to assist in their daily short-term violence risk assessment and management, is integrated into an EPIC-based EHR system.
Study: NCT04650867

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).
Study: NCT06123351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denneroll cervical traction orthodontic
Description: traction for 3 to 15 minutes once daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching and strengthening exercises
Description: strengthening exercises with 10 repetitions twice per day 3 times per week stretching exercises with hold for 20 to 30 seconds 3 repetitions daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum-formed soft occlusal splint
Description: 2 mm thick elastic rubber sheets
Study: NCT06516926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4602
Description: Intravenous infusion, cycle every 21 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4602
Description: Intravenous infusion, cycle every 21 days;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4602
Description: Intravenous infusion, cycle every 21 days;
Study: NCT05706051

Intervention type: OTHER
Group type: OTHER
Intervention: posturography
Description: posturography will be performed when diagnosis of ARHL, in need of hearing aid fitting, is done and after information and written approval from patient. Posturography is performed later when hearing aid fitting and 3months after hearing aid use
Study: NCT06312475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN057
Description: KN057 will be administered subcutaneously once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN057
Description: KN057 will be administered subcutaneously once a week.
Study: NCT05532293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSP008-22
Description: MSP008-22 is a small molecule with demonstrated anticancer activity in-vitro \& in vivo studies. As several anticancer drugs are also good antiviral drugs, it was anticipated that MSP008-22 can also be a promising anti-COVID drug. Accordingly, in vitro assay studies and in an in vivo study in golden Syrian hamster were conducted where MSP008-22 has shown good anti-SARSCoV2 effects.MSP008-22.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets identical in appearance, taste and smell to the tablets of MSP008-22
Study: NCT05113238

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assisted gamete activation
Description: compare two different assisted gamete activation protocols to improve ICSI outcome

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assisted gamete activation
Description: compare two different assisted gamete activation protocols to improve ICSI outcome
Study: NCT05777291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity watch monitoring
Description: Patients will be using activity devices during the study period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep mattress monitoring
Description: Patients will be using sleep mattress during the study period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity counseling
Description: Physical activity counseling in accordance to the Swedish model

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Description: Physical activity counseling in accordance to the Swedish model
Study: NCT04948983

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision aid (DA) for breast cancer screening
Description: The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standarised information for breast cancer screening
Description: Information provided by the Chilean Ministry of Health in regards to access to breast cancer screening (Age, frequency and costs)
Study: NCT05622760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiovisual information
Description: The information provided to this group is in audiovisual format. This information is what has been designed with the aim of reducing the level of anxiety of patients who participate in cervical cancer screening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Written information
Description: The information provided to this group is in written format. This information is what is distributed to patients in the midwife's consultation and is available on the website of the health organization (Osakidetza)
Study: NCT04986358

Intervention type: OTHER
Group type: OTHER
Intervention: Follow up at 2 years
Description: The patients will have a follow-up to carry out 2 years after their intervention in addition to their traditional care
Study: NCT05664568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Participants in intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet
Description: Participants in the intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment of tuberculosis
Description: The control group will be given standard of care treatment of tuberculosis consisting of rifampicin, isoniazid, pyrazinamide and ethambutol
Study: NCT06549257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313, Pfs48/45
Description: Two soluble protein vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313, Pfs48/45
Description: Two soluble protein vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313, Pfs48/45
Description: Two soluble protein vaccines.
Study: NCT05961033

Intervention type: DEVICE
Intervention: Virtual Reality based exercises
Description: Play VR games
Study: NCT00911131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule endoscopy (PillCam ESO)
Description: The capsule endoscope is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EGD
Description: Patients will undergo conventional EGD under conscious sedation for routine screening of esophageal varices.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule endoscopy (PillCam ESO) with abdominal binder
Description: An abdominal binder with and inflatable girdle is wrapped around the stomach prior to swallowing the capsule endoscope. The girdle is inflated to 10mmHg for 10 minutes. The capsule is swallowed by the patient and the routine method for the procedure is performed.
Study: NCT06518434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Cannabis
Description: Medical cannabis oil three times daily
Study: NCT05282953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIO-301
Description: KIO-301 intravitreal injection at ascending doses
Study: NCT06712992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-spinal Direct Current Stimulation
Description: Physiomed- IONOSON-Expert, Germany will be used to deliver SHAM direct current, The Physiomed- IONOSON-Expert, Germany is Two-channel electrotherapy including 21 currents, including direct current. The tsDCS electrodes will be rectangular pieces of saline-soaked synthetic sponge (7 × 8 cm, 56 cm2), to minimize chemical reactions at the electrode-skin interface. The anode will be placed over the spinous process of the eighth thoracic vertebra (T8) and the cathode will be placed on the second lumbar vertebra (L2) according to a modeling study which demonstrated that this configuration had a relevant impact on the distribution of the induced electric field (EF) in the lumbosacral spinal cord for the efficacy of tsDCS.
Study: NCT03977311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU)
Description: -To be used in conjunction with radiation therapy in the treatment of locally advanced cervical carcinoma patients

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -Standard of Care
Study: NCT06712992

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional Exercises
Description: 1. Isometric exercises of spine~   * Hollowing in abdominals.~  * Isometric for back extensors.~2. Bridging exercises.~3. Graded active flexion exercises of spine~4. Graded active extension exercises of spine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercises
Description: 1. Isometric exercises of spine~   * Hollowing in abdominals.~  * Isometric for back extensors.~2. Bridging exercises.~3. Graded active flexion exercises of spine~4. Graded active extension exercises of spine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: SHAM Trans-spinal Direct current stimulation
Description: For a sham tsDCS, the current will be ramped up for 30 seconds turned on for 5 s and then turned off in a ramp shaped fashion, thus inducing skin sensations indistinguishable from anodal tsDCS. This method was shown to achieve a good level of blinding among sessions.~These parameters for sham stimulation were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade usually out in the first 30 s of TsDcs .
Study: NCT04891393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Starbucks brand Via instant coffee. (Caffeine Content: 3 mg / kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Decaffeinated coffee
Description: Starbucks brand Via instant decaffeinated coffee. (Caffeine Content: 15 - 25 mg)
Study: NCT05633303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Substrate guided ablation
Description: Ablation strategy implemented will be dependent on the Arm the patient has been allocated to based on the presence of underlying LVZs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Substrate guided ablation
Description: Ablation strategy implemented will be dependent on the Arm the patient has been allocated to based on the presence of underlying LVZs.
Study: NCT05913037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test group (Group A): FCN-159 8 mg, orally, once daily;
Description: After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Group B): Placebo, orally, once daily;
Description: After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
Study: NCT06505772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine ) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~For example, it begins with an infusion of 4 ml over 10 minutes and then continues the infusion, depending on the weight of the child, at a rate of 1.6 ml/kg/hour.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (NS) for intravenous infusion is supplied in pre-filled syringes of 20 ml, 50 ml, and 100 ml. To maintain blinding in this study, NS is handled identically to the study drug, dexmedetomidine. A physician not involved in the study prepares all injections, randomly assigning either NS or dexmedetomidine using a sealed envelope technique. Prepared syringes are then placed in identical, unmarked infusion pumps.~Infusion Protocol:~Anesthesiologists, blinded to the infusion contents, administer the solutions according to the protocol:~For example,Initial Bolus: 4 ml infused over 10 minutes, Maintenance Infusion: Continued at a rate of 1.6 ml/kg/hour, adjusted to the individual patient's weight.~This process ensures both patient and anesthesiologist remain blinded to the treatment arm, minimizing potential bias throughout the study.
Study: NCT05883241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Device with 2.5% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3-megahertz (MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5% Diclofenac Patches
Description: Topical pain relief-gel worn during treatment via SAM patch.
Study: NCT05303402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHH1-V
Description: COVID-19 Vaccine HIPRA, 40 mcg/dose
Study: NCT06329284

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ELISA
Description: ELISA estimation of serum Midkine, tumor necrosis factor Alfa, superoxide dismutase, malondialdehyde, placental growth factor and placental soluble fms-like tyrosine kinase 1
Study: NCT06205680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAA for topical anaesthesia of the nasal cavity
Description: NAA for topical anaesthesia of the nasal cavity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAA for topical anaesthesia of the nasal cavity
Description: NAA for topical anaesthesia of the nasal cavity
Study: NCT05974059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Preoperative treatment：130mg/m2，iv, 2h，d1，Q3W; Postoperative treatment：130mg/m2，iv, 2h，d1，Q3W;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Preoperative treatment：1000 mg /m2, PO，bid d1-14，Q3W； Postoperative treatment：1000 mg /m2, PO，bid. d1-14，Q3W；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab 10 mg/kg, d1, Q3W
Study: NCT05323058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tulsi extract
Description: 4% topical oral spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzydamine Hydrochloride
Description: 0.15% topical oral spray
Study: NCT05813041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioCaptis
Description: The BioCaptis is a medical device intended to capture cell-free DNA from peripheral blood for use in liquid biopsy. When used as a cartridge filter during an apheresis procedure in which plasma is passed through the device, the BioCaptis binds cfDNA which can be eluted, concentrated, and used as an input for cancer diagnostic tests.
Study: NCT04788368

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical resection with either of the above mentioned techniques

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical resection with either of the above mentioned techniques

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical resection with either of the above mentioned techniques
Study: NCT05194371

Intervention type: RADIATION
Intervention: definitive radiotherapy or definitive chemoradiotherapy
Description: A total dose of radiation therapy should be more than 50Gy
Study: NCT06230601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cough Trick Method
Description: During the Blood Collection Procedure in School-Age Children, one group will use the Cough Trick Method

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pinwheel Blowing method
Description: Pinwheel Blowing method
Study: NCT04825470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplantation
Description: Liver Transplantation
Study: NCT06313788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Possession of a customized placebo analgesic band-aid prior to vaccination or injection
Description: Participants will be told that in order to thank them for doing the marketing interview, as a token of appreciation, they will receive a free band-aid with a customized cartoon of their preference. They will be displayed band-aids with different cartoon images (such as Luffy, minions etc) from which they can freely choose their favorite one . They will be asked to sign their name on the band-aid. This is to establish their sense of ownership. Lastly, with the assistance of the parent, they will be encouraged to anticipate and describe how the owned band-aid is important to them and can help them cope with the forthcoming pain from injection.
Study: NCT06739252

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine Oxaliplatin and 5FU
Description: The perioperative treatment plan includes neoadjuvant therapy and adjuvant therapy. Neoadjuvant therapy consists of three cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), while adjuvant therapy includes two cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), along with additional capecitabine or tegafur as auxiliary maintenance treatment for three cycles. The total treatment duration for the perioperative period is six months. HAIC regimen: gemcitabine (1,000 mg/m2, 2h, d1) + oxaliplatin (35 mg/m2, 2h, d1-2) + 5-FU (0.75g/m2, 22h, d1-2); atezolizumab (PD-L1 inhibitor): 1200 mg, intravenous infusion, administered within 24 hours before HAIC treatment; bevacizumab: 7.5 mg/kg, intravenously infused before HAIC treatment (bevacizumab use is paused during the third neoadjuvant treatment). Each cycle lasts for three weeks.